Skip to content

Post-MI PET Scan Imaging of Inflammation

Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02281305
Enrollment
20
Registered
2014-11-03
Start date
2014-10-31
Completion date
Unknown
Last updated
2014-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

Restoring the patency of the coronary vessels and providing the ischemic myocardium with reperfused blood can cause additional tissue damage. A key element of ischemia and reperfusion (I/R) injury and major determinant of the evolution of damage in the affected myocardium is the inflammatory response. The main objective of the study is to evaluate the efficacy of colchicine in reducing I/R injury by effectively modulating the inflammatory response in the reperfused myocardium.

Interventions

DRUGColchicine

Sponsors

Academy of Athens
CollaboratorOTHER
G.Gennimatas General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* The study will enroll patients 18 years old or older * Who presented to the hospital within twelve (12) hours of the onset of chest pain -Who had ST segment elevation \> 1 mm in two contiguous limb leads or ST segment elevation \> 2 mm in two consecutive precordial leads or new onset of left bundle branch block (LBBB) in a twelve lead electrocardiogram and for whom the decision was made to be taken to the cath lab to perform angioplasty of the coronary vessels.

Exclusion criteria

* Excluded patients: * with age \> 80 years old * with active inflammatory diseases, infectious diseases or known malignancy * under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents * with known hypersensitivity-allergy to colchicine * under chronic treatment with colchicine * with severe renal failure (eGFR \< 30 ml/min/1.73 m2) * with hepatic failure (Child - Pugh class B or C) * presented with cardiac arrest * presented with ventricular fibrillation * presented with cardiogenic shock * with stent thrombosis * with angina within 48 hours before infarction * with previous myocardial infarction in the affected territory * with occlusion of the left main or left circumflex coronary or the right coronary artery or with evidence of coronary collaterals to the region at risk on initial coronary angiography (at the time of admission)

Design outcomes

Primary

MeasureTime frame
Degree of inflammation of the involved myocardium as assessed by the PET scan5 days post-MI

Countries

Greece

Contacts

Primary ContactSpyridon Deftereos, MD
spdeftereos@gmail.com+302107768560
Backup ContactGeorgios Giannopoulos, MD
ggiann@med.uoa.gr+302107768560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026